Dominika Matecka
Dominika Matecka has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Chołuj
The Independent Public Healthcare Institution of the Ministry of the Interior and Administration in Łódź Północna 42 Street, 91–425 Łódź, Poland
10 shared publications - Jakub Marciniak
University Clinical Hospital No. 2 of the Medical University of Łódź 113 Żeromskiego Street, 90-549 Łódź, Poland
10 shared publications - Jakub Mazur
Voivodeship Combined Hospital in Kielce 45 Grunwaldzka Street, 25-736 Kielce, Poland
10 shared publications - Karolina Zarówna
District Hospital Complex in Oleśnica Armii Krajowej Street, 56-400 Oleśnica, Poland
10 shared publications - Mateusz Kosowski
Independent Public Healthcare Institution in Koło 25 Księcia Józefa Poniatowskiego Street, 62-600 Koło, Poland
10 shared publications - Weronika Pura
The Independent Public Healthcare Institution of the Ministry of the Interior and Administration in Łódź Północna 42 Street, 91–425 Łódź, Poland
10 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
LITHIUM AND ALZHEIMER’S DISEASE: POTENTIAL NEUROPROTECTIVE EFFECTS AND THERAPEUTIC PERSPECTIVES
Lithium is an established mood stabilizer whose possible use in Alzheimer’s disease (AD) has emerged from convergent molecular, animal, observational, and early clinical evidence. The principal rationale is that lithium may act on several processes implicated in AD rather than on a single lesion: glycogen synthase kinase-3β (GSK-3β) signaling, tau phosphorylation, amyloid precursor protein processing, neuroinflammation, oxidative and mitochondrial stress, autophagy, neurogenesis, and synaptic plasticity. Animal studies generally report preserved memory and reduced amyloid-related pathology, while small human studies suggest that subtherapeutic lithium may attenuate cognitive decline or modify cerebrospinal-fluid biomarkers. Observational cohorts also associate lithium exposure with lower dementia incidence, but these findings are vulnerable to confounding by indication, comorbidity, treatment adherence, and healthcare use. Evidence is not uniformly positive: a Scottish cohort exposed to extremely low environmental lithium did not support dementia protection, and a recent randomized feasibility trial in mild cognitive impairment found no significant effect on any of six prespecified coprimary outcomes, although one memory measure declined more slowly with lithium. The therapeutic challenge is therefore not simply whether lithium is neuroprotective, but which patients, dose, formulation, exposure duration, and biomarker-defined disease stage are most likely to benefit. Lithium remains an investigational strategy for AD prevention or treatment, not a substitute for established clinical care.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessLITHIUM AND ALZHEIMER’S DISEASE: POTENTIAL NEUROPROTECTIVE EFFECTS AND THERAPEUTIC PERSPECTIVES
Lithium is an established mood stabilizer whose possible use in Alzheimer’s disease (AD) has emerged from convergent molecular, animal, observational, and early clinical evidence. The principal rationale is that lithium may act on several processes implicated in AD rather than on a single lesion: glycogen synthase kinase-3β (GSK-3β) signaling, tau phosphorylation, amyloid precursor protein processing, neuroinflammation, oxidative and mitochondrial stress, autophagy, neurogenesis, and synaptic plasticity. Animal studies generally report preserved memory and reduced amyloid-related pathology, while small human studies suggest that subtherapeutic lithium may attenuate cognitive decline or modify cerebrospinal-fluid biomarkers. Observational cohorts also associate lithium exposure with lower dementia incidence, but these findings are vulnerable to confounding by indication, comorbidity, treatment adherence, and healthcare use. Evidence is not uniformly positive: a Scottish cohort exposed to extremely low environmental lithium did not support dementia protection, and a recent randomized feasibility trial in mild cognitive impairment found no significant effect on any of six prespecified coprimary outcomes, although one memory measure declined more slowly with lithium. The therapeutic challenge is therefore not simply whether lithium is neuroprotective, but which patients, dose, formulation, exposure duration, and biomarker-defined disease stage are most likely to benefit. Lithium remains an investigational strategy for AD prevention or treatment, not a substitute for established clinical care.
- Open Access
- 31 August 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (9) , 461
Neurological and Neuropsychiatric Manifestations of Pediatric Inflammatory Multisystem Syndrome (PIMS/MIS-C): A Narrative Review
Background: Pediatric inflammatory multisystem syndrome (PIMS), also referred to as multisystem inflammatory syndrome in children (MIS-C), is a rare but serious post-infectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection characterized by systemic hyperinflammation and multiorgan involvement. New-onset neurological and psychiatric symptoms have emerged as critical clinical features, occurring in approximately 12–27% of pediatric patients aged 2–15 years (median age, 10 years) and often indicating a more severe disease course. This narrative review aims to provide a comprehensive overview of the current literature regarding the neurological and psychiatric manifestations of PIMS/MIS-C, focusing on epidemiology, pathophysiology, clinical presentation, neuroimaging findings, biomarkers, treatment strategies, and outcomes. Methods: A narrative literature review was conducted to synthesize current evidence on the neurological and psychiatric spectrum of PIMS/MIS-C. Evaluated parameters included clinical presentations ranging from common symptoms (such as headache, encephalopathy, altered mental status, and seizures) to rare complications (such as ischemic stroke, acute disseminated encephalomyelitis, Guillain–Barré syndrome, and cerebral edema), alongside associated psychiatric disturbances, diagnostic findings, and therapeutic approaches. Results: Neurological and psychiatric manifestations significantly impact the clinical trajectory of PIMS/MIS-C. Acute symptoms include headache, encephalopathy, seizures, and psychiatric disturbances like behavioral changes, hallucinations, delirium, anxiety, and sleep disorders. Neuroimaging in many cases reveals reversible lesions of the splenium of the corpus callosum, while electroencephalography typically demonstrates diffuse slowing consistent with encephalopathy. Early recognition and prompt administration of immunomodulatory therapy—primarily intravenous immunoglobulin and corticosteroids—correlate with favorable neurological recovery in the majority of patients. However, current evidence remains largely observational and heterogeneous, precluding definitive causal conclusions regarding this treatment–outcome relationship. Affected children more frequently require intensive care unit admission and remain at risk for persistent cognitive, behavioral, and psychiatric sequelae. Conclusions: Neurological and psychiatric complications in PIMS/MIS-C are clinically significant indicators of disease severity that require vigilant monitoring and early immunomodulatory intervention. Continued multidisciplinary follow-up and prospective studies are essential to elucidate the long-term neurodevelopmental and psychiatric consequences and to optimize therapeutic strategies for these patients.
- 31 August 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (9) , 461
Open AccessNeurological and Neuropsychiatric Manifestations of Pediatric Inflammatory Multisystem Syndrome (PIMS/MIS-C): A Narrative Review
Background: Pediatric inflammatory multisystem syndrome (PIMS), also referred to as multisystem inflammatory syndrome in children (MIS-C), is a rare but serious post-infectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection characterized by systemic hyperinflammation and multiorgan involvement. New-onset neurological and psychiatric symptoms have emerged as critical clinical features, occurring in approximately 12–27% of pediatric patients aged 2–15 years (median age, 10 years) and often indicating a more severe disease course. This narrative review aims to provide a comprehensive overview of the current literature regarding the neurological and psychiatric manifestations of PIMS/MIS-C, focusing on epidemiology, pathophysiology, clinical presentation, neuroimaging findings, biomarkers, treatment strategies, and outcomes. Methods: A narrative literature review was conducted to synthesize current evidence on the neurological and psychiatric spectrum of PIMS/MIS-C. Evaluated parameters included clinical presentations ranging from common symptoms (such as headache, encephalopathy, altered mental status, and seizures) to rare complications (such as ischemic stroke, acute disseminated encephalomyelitis, Guillain–Barré syndrome, and cerebral edema), alongside associated psychiatric disturbances, diagnostic findings, and therapeutic approaches. Results: Neurological and psychiatric manifestations significantly impact the clinical trajectory of PIMS/MIS-C. Acute symptoms include headache, encephalopathy, seizures, and psychiatric disturbances like behavioral changes, hallucinations, delirium, anxiety, and sleep disorders. Neuroimaging in many cases reveals reversible lesions of the splenium of the corpus callosum, while electroencephalography typically demonstrates diffuse slowing consistent with encephalopathy. Early recognition and prompt administration of immunomodulatory therapy—primarily intravenous immunoglobulin and corticosteroids—correlate with favorable neurological recovery in the majority of patients. However, current evidence remains largely observational and heterogeneous, precluding definitive causal conclusions regarding this treatment–outcome relationship. Affected children more frequently require intensive care unit admission and remain at risk for persistent cognitive, behavioral, and psychiatric sequelae. Conclusions: Neurological and psychiatric complications in PIMS/MIS-C are clinically significant indicators of disease severity that require vigilant monitoring and early immunomodulatory intervention. Continued multidisciplinary follow-up and prospective studies are essential to elucidate the long-term neurodevelopmental and psychiatric consequences and to optimize therapeutic strategies for these patients.
- Open Access
- 28 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
HUMAN PAPILLOMAVIRUS (HPV): CURRENT STRATEGIES FOR THE PREVENTION AND TREATMENT OF PRECANCEROUS LESIONS
Background: Human papillomavirus (HPV) infection is the primary etiology of cervical cancer and its immediate precursors, collectively known as cervical intraepithelial neoplasia (CIN). Although primary prevention via prophylactic vaccination and secondary screening have significantly reduced incidence, cervical cancer remains a major global health burden, particularly in low- and middle-income countries. This comprehensive review evaluates the current landscape of HPV virology, pathogenesis, advanced diagnostic risk-stratification biomarkers, and evolving management paradigms. Methods: This review synthesizes current literature regarding high-risk HPV types (predominantly HPV16 and 18), viral oncogene mechanisms (E6 and E7), multi-modal screening protocols, and therapeutic interventions ranging from standard surgical excisions to novel non-invasive modalities. Results: While large loop excision of the transformation zone (LLETZ) remains the gold standard for high-grade CIN, its associated obstetric complications necessitate fertility-sparing alternatives. Recent advances highlight the efficacy of non-invasive modalities—including thermal ablation, photodynamic therapy (PDT), and topical immunomodulators such as imiquimod—which achieve high rates of lesion regression and viral clearance while preserving cervical structural integrity. Furthermore, diagnostic precision has been markedly improved through the integration of molecular markers (p16/Ki-67, DNA methylation signatures, and circulating microRNAs) and emerging microbiome-targeted adjunctive therapies. Conclusions: The management of HPV-associated precancerous lesions is shifting from standardized surgical excision to a personalized, molecularly guided, and fertility-preserving paradigm. Future clinical efforts must focus on expanding global vaccine access while implementing multi-modal, minimally invasive therapeutic strategies.
- 28 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessHUMAN PAPILLOMAVIRUS (HPV): CURRENT STRATEGIES FOR THE PREVENTION AND TREATMENT OF PRECANCEROUS LESIONS
Background: Human papillomavirus (HPV) infection is the primary etiology of cervical cancer and its immediate precursors, collectively known as cervical intraepithelial neoplasia (CIN). Although primary prevention via prophylactic vaccination and secondary screening have significantly reduced incidence, cervical cancer remains a major global health burden, particularly in low- and middle-income countries. This comprehensive review evaluates the current landscape of HPV virology, pathogenesis, advanced diagnostic risk-stratification biomarkers, and evolving management paradigms. Methods: This review synthesizes current literature regarding high-risk HPV types (predominantly HPV16 and 18), viral oncogene mechanisms (E6 and E7), multi-modal screening protocols, and therapeutic interventions ranging from standard surgical excisions to novel non-invasive modalities. Results: While large loop excision of the transformation zone (LLETZ) remains the gold standard for high-grade CIN, its associated obstetric complications necessitate fertility-sparing alternatives. Recent advances highlight the efficacy of non-invasive modalities—including thermal ablation, photodynamic therapy (PDT), and topical immunomodulators such as imiquimod—which achieve high rates of lesion regression and viral clearance while preserving cervical structural integrity. Furthermore, diagnostic precision has been markedly improved through the integration of molecular markers (p16/Ki-67, DNA methylation signatures, and circulating microRNAs) and emerging microbiome-targeted adjunctive therapies. Conclusions: The management of HPV-associated precancerous lesions is shifting from standardized surgical excision to a personalized, molecularly guided, and fertility-preserving paradigm. Future clinical efforts must focus on expanding global vaccine access while implementing multi-modal, minimally invasive therapeutic strategies.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
EVENING BLUE LIGHT EXPOSURE AND SLEEP QUALITY: MECHANISMS, CONSEQUENCES, AND PREVENTIVE STRATEGIES — A NARRATIVE REVIEW
Background: Blue light exposure from digital devices has become a prevalent environmental factor affecting circadian rhythms and sleep quality. Objective: This review aims to evaluate the physiological mechanisms, sleep disturbances, and psychological consequences associated with evening blue light exposure. Methodology: A narrative synthesis of current literature was conducted, focusing on the effects of short-wavelength light (400-500 nm) on melatonin suppression, sleep architecture, and related health outcomes. Results: Evidence suggests that artificial blue light is an important contributing factor to delayed sleep onset, reduced sleep duration, and impaired sleep efficiency. Furthermore, growing evidence indicates that circadian disruption and evening screen exposure are associated with poorer mood outcomes and digital eye strain. Conclusions: While blue light-filtering technologies offer limited objective benefits, behavioral and environmental interventions—such as limiting evening screen time—remain the most effective preventive strategies to mitigate the adverse effects of digital device use.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessEVENING BLUE LIGHT EXPOSURE AND SLEEP QUALITY: MECHANISMS, CONSEQUENCES, AND PREVENTIVE STRATEGIES — A NARRATIVE REVIEW
Background: Blue light exposure from digital devices has become a prevalent environmental factor affecting circadian rhythms and sleep quality. Objective: This review aims to evaluate the physiological mechanisms, sleep disturbances, and psychological consequences associated with evening blue light exposure. Methodology: A narrative synthesis of current literature was conducted, focusing on the effects of short-wavelength light (400-500 nm) on melatonin suppression, sleep architecture, and related health outcomes. Results: Evidence suggests that artificial blue light is an important contributing factor to delayed sleep onset, reduced sleep duration, and impaired sleep efficiency. Furthermore, growing evidence indicates that circadian disruption and evening screen exposure are associated with poorer mood outcomes and digital eye strain. Conclusions: While blue light-filtering technologies offer limited objective benefits, behavioral and environmental interventions—such as limiting evening screen time—remain the most effective preventive strategies to mitigate the adverse effects of digital device use.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
BURNOUT SYNDROME AMONG HEALTHCARE PROFESSIONALS: A NARRATIVE REVIEW OF EPIDEMIOLOGY, CLINICAL CONSEQUENCES, AND INTERVENTIONS
Background: Burnout is a syndrome arising from chronic, poorly managed workplace stress and is characterized by emotional exhaustion, depersonalization, and reduced personal accomplishment. It is highly prevalent among healthcare professionals and has been recognized by the World Health Organization as an occupational phenomenon. Aim: This narrative review summarizes current evidence on the epidemiology, risk factors, clinical consequences, and management of burnout among healthcare professionals, with particular attention to its impact on patient care and safety. Methods: We reviewed recent international literature, including epidemiological studies, systematic reviews, and intervention trials addressing burnout in physicians, nurses, and allied health workers. Results: Burnout affects a substantial proportion of healthcare workers, with reported prevalence exceeding 50% among physicians and approximately one-third among nurses. Frequently reported risk factors include excessive workload, long working hours, insufficient staffing, limited organizational support, and short sleep duration, whereas supportive work environments and individual resilience appear protective. Burnout is consistently associated with increased medical errors, reduced quality of care, lower adherence to safety protocols, and comorbid mental health problems. Organization-directed interventions are generally more effective than individual approaches alone, although combined strategies appear most beneficial. Conclusions: Burnout is a prevalent occupational phenomenon with important consequences for both clinicians and patients. Effective mitigation requires system-level interventions addressing work organization and leadership, complemented by individual support, together with further research in underrepresented populations and settings.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessBURNOUT SYNDROME AMONG HEALTHCARE PROFESSIONALS: A NARRATIVE REVIEW OF EPIDEMIOLOGY, CLINICAL CONSEQUENCES, AND INTERVENTIONS
Background: Burnout is a syndrome arising from chronic, poorly managed workplace stress and is characterized by emotional exhaustion, depersonalization, and reduced personal accomplishment. It is highly prevalent among healthcare professionals and has been recognized by the World Health Organization as an occupational phenomenon. Aim: This narrative review summarizes current evidence on the epidemiology, risk factors, clinical consequences, and management of burnout among healthcare professionals, with particular attention to its impact on patient care and safety. Methods: We reviewed recent international literature, including epidemiological studies, systematic reviews, and intervention trials addressing burnout in physicians, nurses, and allied health workers. Results: Burnout affects a substantial proportion of healthcare workers, with reported prevalence exceeding 50% among physicians and approximately one-third among nurses. Frequently reported risk factors include excessive workload, long working hours, insufficient staffing, limited organizational support, and short sleep duration, whereas supportive work environments and individual resilience appear protective. Burnout is consistently associated with increased medical errors, reduced quality of care, lower adherence to safety protocols, and comorbid mental health problems. Organization-directed interventions are generally more effective than individual approaches alone, although combined strategies appear most beneficial. Conclusions: Burnout is a prevalent occupational phenomenon with important consequences for both clinicians and patients. Effective mitigation requires system-level interventions addressing work organization and leadership, complemented by individual support, together with further research in underrepresented populations and settings.
- Open Access
- 14 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
THE ROLE OF HORMONAL AND NON-HORMONAL MARKERS IN ASSESSING PERINATAL STRESS AND ITS CLINICAL IMPLICATIONS
Background: Prenatal and perinatal stress activates the maternal and fetal HPA axis, releasing biomarkers that can cross the placenta. In high concentrations, these substances may lead to congenital malformations, preterm labor, or intrauterine growth restriction (IUGR). Despite their potential, endogenous biomarkers are not yet part of standard gynecological diagnostics. Aim: This paper analyzes recent reports on hormonal and non-hormonal perinatal stress biomarkers to evaluate their application in assessing health risks for mothers and fetuses. Material and Methods: This literature review examines clinical trials and observational studies from the late 20th and early 21st centuries. It focuses on laboratory techniques such as ELI-SA, HPLC, and radioimmunoassay used to measure stress markers in maternal serum, cord blood, amniotic fluid, and urine. Results: Studies show that copeptin levels rise significantly during fetal hypoxia and IUGR, aiding ultrasonographic differentiation. Maternal cortisol levels correlate negatively with birth weight and increase the risk of infants being small for gestational age (SGA). ACTH and CRH serve as indicators of HPA axis maturity and predictors of preterm birth. Regarding non-hormonal markers, malondialdehyde and 8-isoprostane are sensitive indicators of oxidative stress linked to preeclampsia. Furthermore, elevated proinflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha) are closely associated with intrauterine infections and the onset of preterm labor. Conclusions: Perinatal stress biomarkers offer significant prognostic value for identifying risks of preterm labor and developmental pathologies. While cortisol currently has the greatest clinical utility, copeptin and malondialdehyde are noted for their stability and potential for routine screening. Further clinical trials are necessary to integrate these markers into standard obstetric care.
- 14 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessTHE ROLE OF HORMONAL AND NON-HORMONAL MARKERS IN ASSESSING PERINATAL STRESS AND ITS CLINICAL IMPLICATIONS
Background: Prenatal and perinatal stress activates the maternal and fetal HPA axis, releasing biomarkers that can cross the placenta. In high concentrations, these substances may lead to congenital malformations, preterm labor, or intrauterine growth restriction (IUGR). Despite their potential, endogenous biomarkers are not yet part of standard gynecological diagnostics. Aim: This paper analyzes recent reports on hormonal and non-hormonal perinatal stress biomarkers to evaluate their application in assessing health risks for mothers and fetuses. Material and Methods: This literature review examines clinical trials and observational studies from the late 20th and early 21st centuries. It focuses on laboratory techniques such as ELI-SA, HPLC, and radioimmunoassay used to measure stress markers in maternal serum, cord blood, amniotic fluid, and urine. Results: Studies show that copeptin levels rise significantly during fetal hypoxia and IUGR, aiding ultrasonographic differentiation. Maternal cortisol levels correlate negatively with birth weight and increase the risk of infants being small for gestational age (SGA). ACTH and CRH serve as indicators of HPA axis maturity and predictors of preterm birth. Regarding non-hormonal markers, malondialdehyde and 8-isoprostane are sensitive indicators of oxidative stress linked to preeclampsia. Furthermore, elevated proinflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha) are closely associated with intrauterine infections and the onset of preterm labor. Conclusions: Perinatal stress biomarkers offer significant prognostic value for identifying risks of preterm labor and developmental pathologies. While cortisol currently has the greatest clinical utility, copeptin and malondialdehyde are noted for their stability and potential for routine screening. Further clinical trials are necessary to integrate these markers into standard obstetric care.
- Open Access
- 6 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
IMPACT OF COMMON CHRONIC DISEASES ON SEMEN QUALITY: A NARRATIVE REVIEW
Background. Chronic diseases, including obesity, type 2 diabetes, cardiovascular diseases, and autoimmune conditions, represent a significant threat to male fertility. These conditions disrupt testicular homeostasis through interconnected pathophysiological mechanisms, leading to the deterioration of semen parameters and sperm genomic integrity. Aim. This narrative review aims to analyze the impact of common chronic diseases on semen quality and to discuss the integrated molecular and systemic mechanisms underlying male infertility in these clinical conditions. Material and methods. A narrative review of current scientific literature was conducted, focusing on clinical and experimental studies regarding the effects of metabolic, cardiovascular, autoimmune, renal, and hepatic disorders on male reproductive functions. Key pathomechanisms, including oxidative stress, inflammation, and hormonal dysregulation, were analyzed. Results. Five primary pathways leading to testicular dysfunction were identified: (1) oxidative stress causing lipid peroxidation and decreased sperm motility; (2) chronic inflammation disrupting the blood-testis barrier; (3) HPG axis dysregulation leading to hypogonadism; (4) endothelial dysfunction impairing testicular microcirculation and thermoregulation; and (5) sperm DNA damage. It was shown that patients with diabetes, hypertension, and inflammatory joint diseases exhibit significantly lower sperm concentration, volume, and motility compared to control groups. Conclusions. Chronic diseases exert a multidirectional, negative impact on semen quality, and the degree of fertility impairment often correlates with disease activity and stage. Management of metabolic and cardiovascular health, along with inflammatory control, is crucial for preserving male reproductive potential.
- 6 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessIMPACT OF COMMON CHRONIC DISEASES ON SEMEN QUALITY: A NARRATIVE REVIEW
Background. Chronic diseases, including obesity, type 2 diabetes, cardiovascular diseases, and autoimmune conditions, represent a significant threat to male fertility. These conditions disrupt testicular homeostasis through interconnected pathophysiological mechanisms, leading to the deterioration of semen parameters and sperm genomic integrity. Aim. This narrative review aims to analyze the impact of common chronic diseases on semen quality and to discuss the integrated molecular and systemic mechanisms underlying male infertility in these clinical conditions. Material and methods. A narrative review of current scientific literature was conducted, focusing on clinical and experimental studies regarding the effects of metabolic, cardiovascular, autoimmune, renal, and hepatic disorders on male reproductive functions. Key pathomechanisms, including oxidative stress, inflammation, and hormonal dysregulation, were analyzed. Results. Five primary pathways leading to testicular dysfunction were identified: (1) oxidative stress causing lipid peroxidation and decreased sperm motility; (2) chronic inflammation disrupting the blood-testis barrier; (3) HPG axis dysregulation leading to hypogonadism; (4) endothelial dysfunction impairing testicular microcirculation and thermoregulation; and (5) sperm DNA damage. It was shown that patients with diabetes, hypertension, and inflammatory joint diseases exhibit significantly lower sperm concentration, volume, and motility compared to control groups. Conclusions. Chronic diseases exert a multidirectional, negative impact on semen quality, and the degree of fertility impairment often correlates with disease activity and stage. Management of metabolic and cardiovascular health, along with inflammatory control, is crucial for preserving male reproductive potential.
- Open Access
- 2 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
EFFECTS OF ANABOLIC-ANDROGENIC STEROIDS ON MENTAL HEALTH - COMPREHENSIVE REVIEW
This review summarizes current information on the mechanisms and adverse outcomes of anabolic-androgenic steroid (AAS) usage. Chronic use of AAS induces significant structural and functional changes in the brain, especially in the prefrontal cortex, hippocampus, and amygdala, through monoaminergic and GABAergic dysregulation, alterations in the tryptophan-kynurenine pathway, and neuroinflammation. Moreover, abuse of AAS causes remodeling of fronto-limbic circuits, as well as suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Clinically, excessive AAS consumption is associated with psychotic, depressive, and anxiety-related symptoms, cognitive decline, and increased aggressive behaviors.
- 2 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessEFFECTS OF ANABOLIC-ANDROGENIC STEROIDS ON MENTAL HEALTH - COMPREHENSIVE REVIEW
This review summarizes current information on the mechanisms and adverse outcomes of anabolic-androgenic steroid (AAS) usage. Chronic use of AAS induces significant structural and functional changes in the brain, especially in the prefrontal cortex, hippocampus, and amygdala, through monoaminergic and GABAergic dysregulation, alterations in the tryptophan-kynurenine pathway, and neuroinflammation. Moreover, abuse of AAS causes remodeling of fronto-limbic circuits, as well as suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Clinically, excessive AAS consumption is associated with psychotic, depressive, and anxiety-related symptoms, cognitive decline, and increased aggressive behaviors.
- Open Access
- 23 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
PHARMACOLOGICAL AND SURGICAL TREATMENT OF OBESITY: INTEGRATING THE ROLES OF INFLAMMATION AND GUT DYSBIOSIS- REVIEW
Obesity is a metabolic disease characterized by chronic systemic inflammation and dysbiosis of gut microbiota. This review explores relationships between obesity, inflammatory pathways, and gut microbiome composition within a clinical perspective, concentrating on pharmacological and surgical options. Current therapeutic strategies consist of GLP-1 receptor agonists, orlistat, naltrexone-bupropion combination therapy, and bariatric surgery. Significantly, therapeutic advantages go far beyond weight decrease to consist of improved microbial diversity, decreased inflammation (reflected as a decrease in inflammatory markers such as CRP, IL-6, and TNF-α), and metabolic outcomes. The present review demonstrates that successful obesity therapy requires both the normalisation of gut microbial function and the elimination of systemic inflammation, underscoring the significance of microbiota-related modalities for total obesity treatment.
- 23 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessPHARMACOLOGICAL AND SURGICAL TREATMENT OF OBESITY: INTEGRATING THE ROLES OF INFLAMMATION AND GUT DYSBIOSIS- REVIEW
Obesity is a metabolic disease characterized by chronic systemic inflammation and dysbiosis of gut microbiota. This review explores relationships between obesity, inflammatory pathways, and gut microbiome composition within a clinical perspective, concentrating on pharmacological and surgical options. Current therapeutic strategies consist of GLP-1 receptor agonists, orlistat, naltrexone-bupropion combination therapy, and bariatric surgery. Significantly, therapeutic advantages go far beyond weight decrease to consist of improved microbial diversity, decreased inflammation (reflected as a decrease in inflammatory markers such as CRP, IL-6, and TNF-α), and metabolic outcomes. The present review demonstrates that successful obesity therapy requires both the normalisation of gut microbial function and the elimination of systemic inflammation, underscoring the significance of microbiota-related modalities for total obesity treatment.
- Open Access
- 20 December 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (4(48))
MULTIFACTORIAL DETERMINANTS OF OBESITY: THE ROLES OF HORMONES, GENETICS, INFLAMMATION AND GUT MICROBIOTA – REVIEW
Obesity is a multifactorial chronic disease resulting from the interaction of genetic, hormonal, inflammatory, and microbial factors. While caloric imbalance contributes to its pathogenesis, pathways involving molecular mechanisms—such as leptin–melanocortin pathway dysfunction, adipokine dysregulation, and microbiota-induced inflammation—are also significant. Adipose tissue inflammation is characterized by macrophage infiltration, activation of MAPK and NF-κB pathways, and abnormal adipokine secretion, all of which lead to insulin resistance and metabolic dysfunction. Genetic factors, including mutations in the LEP, LEPR, POMC, and MC4R genes, can disrupt appetite regulation and predispose individuals to early-onset obesity. Syndromic forms of obesity, such as Prader–Willi and Bardet–Biedl syndromes, further highlight chromosomal influences. Hormonal imbalances, including those involving ghrelin, GLP-1, and CCK, also affect energy expenditure and appetite regulation. Additionally, gut dysbiosis contributes to systemic inflammation through increased levels of lipopolysaccharides (LPS) and decreased production of short-chain fatty acids, which maintain metabolic endotoxemia. These patterns of evidence underscore the need for integrative interventions targeting endocrine, inflammatory, and microbial pathways. Further research is required to clarify gene– microbiota–hormone interactions and to develop personalized therapeutic intervention.
- 20 December 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (4(48))
Open AccessMULTIFACTORIAL DETERMINANTS OF OBESITY: THE ROLES OF HORMONES, GENETICS, INFLAMMATION AND GUT MICROBIOTA – REVIEW
Obesity is a multifactorial chronic disease resulting from the interaction of genetic, hormonal, inflammatory, and microbial factors. While caloric imbalance contributes to its pathogenesis, pathways involving molecular mechanisms—such as leptin–melanocortin pathway dysfunction, adipokine dysregulation, and microbiota-induced inflammation—are also significant. Adipose tissue inflammation is characterized by macrophage infiltration, activation of MAPK and NF-κB pathways, and abnormal adipokine secretion, all of which lead to insulin resistance and metabolic dysfunction. Genetic factors, including mutations in the LEP, LEPR, POMC, and MC4R genes, can disrupt appetite regulation and predispose individuals to early-onset obesity. Syndromic forms of obesity, such as Prader–Willi and Bardet–Biedl syndromes, further highlight chromosomal influences. Hormonal imbalances, including those involving ghrelin, GLP-1, and CCK, also affect energy expenditure and appetite regulation. Additionally, gut dysbiosis contributes to systemic inflammation through increased levels of lipopolysaccharides (LPS) and decreased production of short-chain fatty acids, which maintain metabolic endotoxemia. These patterns of evidence underscore the need for integrative interventions targeting endocrine, inflammatory, and microbial pathways. Further research is required to clarify gene– microbiota–hormone interactions and to develop personalized therapeutic intervention.